Aaron Franke M.D., M.S highlights current challenges facing the shifting paradigm of early-stage NSCLC management. He analyzes recent data supporting novel therapeutic approaches vs standard of care in resectable NSCLC. He reviews anticipated and ongoing clinical trials using IO-based therapy in early-stage NSCLC. 

Additionally, he examines knowledge gaps and challenges facing adopting the neoadjuvant paradigm in clinical practice as he helps us to understand clinical parameters that qualify patients for ICI-based neoadjuvant therapy and he highlights how to plan therapy for patients with stage I-III NSCLC based on individual patient considerations, expert recommendations, and available clinical data.